Synlogic, INC

Caldera Therapeutics and Synlogic are merging in an all-stock transaction, with Caldera to operate as the combined entity and seeking Nasdaq listing, supported by a $278 million private placement.

Synlogic, Inc. has withdrawn its Nasdaq listing appeal and will delist, planning to trade on the OTCQB Venture Market after being deemed a public shell.

Synlogic, Inc. announced its decision to withdraw its request for a Nasdaq hearing, leading to its delisting and a planned transition to OTC Markets Group.

Synlogic, Inc. stockholders approved a new 2025 Equity Incentive Plan, authorizing 1,000,000 shares plus potential additions, and reelected directors at their annual meeting.

Synlogic, Inc. received a notice from Nasdaq indicating its belief that the company is a public shell, initiating potential delisting proceedings.

Michael Heffernan resigned from Synlogic's board of directors and associated committees, effective immediately, with no reported disagreements with the company.

Synlogic Inc. reported a net income of $681,000 for the first quarter of 2026, a significant increase from the prior year, as the company continues its strategic review process.

Synlogic, Inc. reported a significantly reduced net loss for the nine months ended September 30, 2025, as it continues to evaluate strategic alternatives following the discontinuation of its lead clinical trial.

Synlogic reported a significantly reduced net loss and cash burn in Q2 2025 as it continues to evaluate strategic alternatives following the discontinuation of its lead clinical trial.

Synlogic reports a net income of $0.3 million for Q1 2025, driven by a gain in the fair value of purchase warrants, while the company continues to explore strategic alternatives.

Synlogic discontinues its pivotal Phase 3 trial for labafenogene marselecobac (SYNB1934) and initiates a strategic review process, including potential merger or sale, while significantly reducing its workforce.

Synlogic discontinued its pivotal Phase 3 trial for labafenogene marselecobac (SYNB1934) and is exploring strategic alternatives, including a potential merger or sale of the company, following a corporate restructuring.

Synlogic, Inc. filed an amendment to its 2025 Annual Report to provide previously omitted disclosures regarding corporate governance, executive compensation, and related party transactions.

Synlogic, a biopharmaceutical company, has discontinued its lead clinical program and delisted from Nasdaq, now focusing on strategic alternatives as a public shell company.

Synlogic files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and accounting fees.

Synlogic halts its pivotal PKU study due to unfavorable internal review, shifting focus to strategic options like a merger or sale to boost stockholder value.

Synlogic, Inc. has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Synlogic discontinues its pivotal Phase 3 study for labafenogene marselecobac (SYNB1934) in PKU and initiates a strategic review process, including a possible merger or sale of the company.

Synlogic and Caldera Therapeutics announce a merger agreement, creating a combined entity focused on advancing CLD-423 for inflammatory bowel disease, supported by a $278 million private placement.

SYNLOGIC's Principal Executive and Financial Officer, Mary Beth Dooley, sold 157 shares of common stock to cover tax liabilities related to a restricted stock award.

Director Richard P. Shea acquired 15,000 shares of Synlogic, Inc. restricted stock on April 26, 2025, which will fully vest on December 15, 2025, pending continued service as a Non-Employee Director.

Director James P. Flynn acquired 15,000 shares of Synlogic, Inc. restricted stock on April 26, 2025, as part of the Non-Employee Director Compensation Program.

Mary Beth Dooley, Principal Executive Officer and Principal Financial Officer of Synlogic, Inc., sold 144 shares of common stock on April 2, 2025, to cover tax liabilities associated with vesting restricted stock awards.

Mary Beth Dooley, Principal Executive Officer and Principal Financial Officer of Synlogic, Inc., sold 2,107 shares of common stock to cover tax liabilities related to a restricted stock award.

Synlogic, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 15, 2025, seeking approval for director elections, executive compensation, a new equity incentive plan, and auditor ratification.

Synlogic, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on December 4, 2024, to vote on director election, executive compensation, and auditor ratification.

New Enterprise Associates 14, L.P. and affiliated entities have filed an amendment to their Schedule 13D, detailing their support for Synlogic, Inc.'s merger with Caldera Therapeutics, Inc.

Reporting persons Funicular Funds, LP, Cable Car Capital, LP, and Jacob Ma-Weaver have filed an amendment to their Schedule 13D, detailing their support for Synlogic's merger with Caldera Therapeutics, Inc.

Cable Car Capital and Funicular Funds propose to acquire Synlogic for $0.64 per share, representing a 28.3% stake.

Baslake Partners, LP, along with Baselake Management, LLC and David Paolella, reported a passive 9.7% beneficial ownership stake in Synlogic, Inc., totaling 1,140,000 shares.

Bradley L. Radoff has amended his beneficial ownership in Synlogic, Inc., reporting a 4.4% stake as of September 30, 2025.

John A. Kryzanowski has filed an amended Schedule 13G, reporting a passive beneficial ownership of 6.27% of Synlogic, Inc.'s common stock as of December 31, 2024.